Condition: Chronic Coronary Syndrome · Sponsor: Yonsei University
The purpose of this study is to evaluate the clinical utility of zastaprazan compared to proton pump inhibitors (PPIs) in patients receiving dual antiplatelet therapy (DAPT) including clopidogrel after percutaneous coronary intervention (PCI), by comparing their effects on platelet reactivity.
This description comes directly from the study's public registry record.
Yongcheol Kim, MD, PhD · +82-031-5189-8967 · yongcheol@yuhs.ac
Always discuss trial participation with your own doctor first.
| Yongin Severance Hospital, Yonsei University | Yongin-si, Gyeonggi-do, South Korea | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07471867